课题基金 / 基金详情

Apolipoprotein B and Control of S. aureus Quorum Sensing

Apolipoprotein B and Control of S. aureus Quorum Sensing
载脂蛋白 B 和金黄色葡萄球菌群体感应的控制
批准号:
8811089
负责人:
Pamela Ranel Hall
金额:
$39.75万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-15 至 2017-01-31

项目摘要

项目成果

Pamela Ranel Hall的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Antibiotic resistant Staphylococcus aureus infections are emerging as a major public health threat in the US and around the world. Particularly problematic are methicillin resistant S. aureus (MRSA) infections of the USA300 and USA400 PFGE types that cause necrotic skin and lung infections. While progress has been made in elucidating the MRSA virulence factors that contribute to infection and their control by a quorum sensing operon, agr, very little is known about host factors that contribute to susceptibility. Typically, S. aureus causes opportunistic infections in those at the extremes of age and with serious medical conditions. However, USA300 and USA400 MRSA infections are presenting in young immunocompetent adults suggesting that barriers previously unrecognized are essential to control these infections. Quorum sensing in S. aureus is regulated in part by a four gene operon, agr, which includes a thiolactone peptide pheromone (AIP) and a two component sensor regulator that upon activation leads to transcriptional control of over 160 different genes involved in virulence. We identified apolipoprotein B, a component of lipid metabolism, as an essential barrier to invasive S. aureus skin infection and that the mechanism involves control of agr signaling. Specifically, apoB binds to and sequesters AIP thus preventing activation of the agr operon. Because dermonecrotic skin infections predominate in these MRSA infections, extravasation of plasma apoB into infected skin could provide early control of agr and thus limit the production of virulence factors required to evade innate immune killing and clearance of the bacteria. Because apoB is the major structural protein of both VLDL and LDL, aspects of lipoprotein metabolism, including clearance by scavenger receptors (e.g. CD36), could contribute to this host defense mechanism. Therefore, the hypothesis we are testing is that the amino terminal domain of apoB and subsequent clearance through CD36 are essential for host defense against invasive MRSA infection. To test this hypothesis we will pursue the following specific aims: 1) To define the domain(s) of apoB sufficient for binding and functional antagonism of AIP in vitro; 2) To determine the in vivo contribution of apoB to the outcome of agr-dependent invasive infections of strains from the most clinically relevant community-acquired MRSA agr types: USA300 (agr1) and USA400 (agr3): 3) To determine the contribution of CD36 clearance of apoB-AIP complexes to protection against agr dependent invasive MRSA infections.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1501835
发表时间: 2016-01-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Manifold-Wheeler BC, Elmore BO, Triplett KD, Castleman MJ, Otto M, Hall PR]
通讯作者: Hall PR
DOI: 10.1371/journal.pone.0125027
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者: [Elmore BO, Triplett KD, Hall PR]
通讯作者: Hall PR
DOI: 10.4049/jimmunol.1500500
发表时间: 2015-09-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Castleman MJ, Febbraio M, Hall PR]
通讯作者: Hall PR
Vaccine-mediated control of bacterial virulence regulation and infection
Vaccine-mediated control of bacterial virulence regulation and infection
Vaccine-mediated control of bacterial virulence regulation and infection
Inducing Immune Control of Bacterial Virulence Regulation
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: